Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2025

11.12.24 22:04 Uhr

Werte in diesem Artikel

STATESVILLE, N.C., Dec. 11, 2024 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its second quarter ended October 31, 2024.

Kewaunee Scientific Corporation (PRNewsFoto/Kewaunee Scientific Corporation)

Fiscal Year 2025 Second Quarter Results:

Sales during the second quarter of fiscal year 2025 were $47,764,000, a decrease of 5.3% compared to sales of $50,436,000 from the prior year's second quarter. Pre-tax earnings for the quarter were $3,931,000 compared to $4,845,000 for the prior year quarter, a decrease of 18.9%. Net earnings were $3,008,000 compared to net earnings of $2,732,000 for the prior year quarter. EBITDA1 for the quarter was $4,883,000 compared to $5,662,000 for the prior year quarter. Diluted earnings per share was $1.01 compared to diluted earnings per share of $0.93 in the prior year quarter.

The Company's order backlog was at a historically high level of $184.4 million on October 31, 2024, as compared to $146.3 million on October 31, 2023, and $155.6 million on April 30, 2024.

Domestic Segment - Domestic sales for the quarter were $36,409,000, an increase of 6.5% from sales of $34,185,000 in the prior year quarter. Domestic segment net earnings was $4,524,000 compared to $3,054,000 in the prior year quarter. Domestic segment EBITDA was $6,838,000 compared to $5,230,000 for the prior year quarter. The increase in Domestic sales and earnings was primarily driven by higher product demand.

International Segment - International sales for the quarter were $11,355,000, a decrease of 30.1% from sales of $16,251,000 in the prior year quarter. International segment net earnings was $356,000 compared to $525,000 in the prior year quarter. International segment EBITDA was $592,000 compared to $1,635,000 for the prior year quarter. The decline in sales is attributable to customer construction site delays in India which pushed out the timing of deliveries.

Corporate Segment – Corporate segment pre-tax net loss was $2,444,000 for the quarter, as compared to a pre-tax net loss of $1,243,000 in the prior year quarter. Corporate segment EBITDA for the quarter was ($2,547,000) compared to corporate segment EBITDA of ($1,203,000) for the prior year quarter. The change in EBITDA was primarily driven by an increase in professional service and other fees during the quarter related to the acquisition of Nu Aire, Inc., which closed on November 1, 2024, and costs incurred related to Sarbanes-Oxley 404(b) compliance readiness.

Total cash on hand on October 31, 2024 was $29,664,000, as compared to $25,938,000 on April 30, 2024. Working capital was $59,965,000, as compared to $52,144,000 at the end of the second quarter last year and $56,037,000 on April 30, 2024.

The Company had short-term debt of $805,000 as of October 31, 2024, as compared to $3,099,000 on April 30, 2024. Long-term debt was $28,047,000 on October 31, 2024, as compared to $28,479,000 on April 30, 2024. The building lease from the Company's December 2021 sale-leaseback transaction accounts for $27,782,000 of the long-term debt on October 31, 2024 and $28,133,000 of the long-term debt on April 30, 2024. Long-term debt, net of the sale-leaseback transaction, was $265,000 on October 31, 2024 as compared to $346,000 on April 30, 2024. The Company's debt-to-equity ratio on October 31, 2024 was 0.59-to-1, as compared to 0.70-to-1 on April 30, 2024. The Company's debt-to-equity ratio, net of the sale-leaseback transaction, on October 31, 2024 was 0.14-to-1, as compared to 0.20-to-1 on April 30, 2024.

"Our financial performance for the second quarter of fiscal year 2025 was strong," said Thomas D. Hull III, Kewaunee's President and Chief Executive Officer. "Domestic segment operating performance improved compared to last year's second quarter as a result of higher product demand, highlighting our continued health and advantage in the market. As discussed during the first quarter of fiscal year 2025, customer construction site delays in India on multiple projects continue to impact our ability to ship products and deliver services, leading to a decrease in sales and earnings when compared to the prior year second quarter."

"Looking ahead, our backlog remains very healthy, demonstrating the continued vitality and investment in the markets in which Kewaunee participates and the success both Kewaunee and our channel partners continue to achieve in the marketplace. The strength of Kewaunee's backlog positions the company well to deliver another strong year for our fiscal year."

"Additionally, on November 1, 2024, Kewaunee announced the acquisition of Nu Aire, Inc.," Hull continued. "Nu Aire is renowned for its manufacturing of robust containment solutions, such as biological safety cabinets, airflow products, and more, which serve a diverse range of industries. While not reflected in our second quarter fiscal year 2025 results, Nu Aire will be included going forward, beginning with our third quarter fiscal year 2025 results. It is worth noting the company incurred expenses related to the acquisition of $2.3 million in the current fiscal year, which are outlined in the attached exhibits."

"The acquisition of Nu Aire presents a unique opportunity for Kewaunee to expand its capabilities, allowing the combined organization to better meet the diverse needs of end-users in laboratory furnishings and, through Nu Aire's established distribution partners, reach regions where Kewaunee has not previously had a presence. This move accelerates the Company's vision of becoming the market leader in the design and manufacturing of laboratory furniture and technical products essential for outfitting the laboratories of tomorrow."

1 EBITDA is a non-GAAP financial measure. See the table below for a reconciliation of EBITDA and segment EBITDA to net earnings (loss), the most directly comparable GAAP measure.

 

EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA Reconciliation

(Unaudited)

($ in thousands)

Quarter Ended October 31, 2023


Domestic


International


Corporate


Consolidated

Net Earnings (Loss)


$                  3,054


$                     525


$                   (847)


$                  2,732

Add/(Less):









Interest Expense


323


35


14


372

Interest Income



(205)


(22)


(227)

Income Taxes


1,232


1,179


(396)


2,015

Depreciation and Amortization


621


101


48


770

EBITDA


$                  5,230


$                  1,635


$                (1,203)


$                  5,662










Quarter Ended October 31, 2024


Domestic


International


Corporate


Consolidated

Net Earnings (Loss)


$                  4,524


$                     356


$                (1,872)


$                  3,008

Add/(Less):









Interest Expense


413


19


10


442

Interest Income



(133)


(156)


(289)

Income Taxes


1,241


247


(572)


916

Depreciation and Amortization


660


103


43


806

EBITDA


$                  6,838


$                     592


$                (2,547)


$                  4,883

Professional & Other Fees




                   1,5402


1,540

Adjusted EBITDA


$                  6,838


$                     592


$                (1,007)


$                  6,423










Year to Date October 31, 2023


Domestic


International


Corporate


Consolidated

Net Earnings (Loss)


$                  5,765


$                     994


$                (1,553)


$                  5,206

Add/(Less):









Interest Expense


703


71


28


802

Interest Income



(418)


(23)


(441)

Income Taxes


2,145


1,461


(694)


2,912

Depreciation and Amortization


1,195


197


96


1,488

EBITDA


$                  9,808


$                  2,305


$                (2,146)


$                  9,967










Year to Date October 31, 2024


Domestic


International


Corporate


Consolidated

Net Earnings (Loss)


$                  7,395


$                     819


$                (3,013)


$                  5,201

Add/(Less):









Interest Expense


854


40


20


914

Interest Income



(307)


(329)


(636)

Income Taxes


2,005


526


(1,423)


1,108

Depreciation and Amortization


1,322


210


89


1,621

EBITDA


$                11,576


$                  1,288


$                (4,656)


$                  8,208

Professional & Other Fees




                   2,2703


2,270

Adjusted EBITDA


$                11,576


$                  1,288


$                (2,386)


$                10,478

______________________________

2 Professional and other fees  incurred during the three months ended October 31, 2024 related to the Company's acquisition of Nu Aire, Inc. ("Nu Aire"), which closed on November 1, 2024

3 Professional and other fees incurred during the six months ended October 31, 2024 related to the Company's acquisition of Nu Aire

 

Adjusted Consolidated Statement of Operations Reconciliation

(Unaudited)

($ in thousands, except per share amounts)


Three Months Ended October 31,


As Reported
2024


Professional
& Other Fees


Adjusted
2024


2023

Net sales

$      47,764


$              —


$       47,764


$      50,436

Cost of products sold

33,812



33,812


36,968

Gross profit

13,952



13,952


13,468

Operating expenses

9,518


          1,2164


8,302


8,359

Operating profit

4,434


1,216


5,650


5,109

Pension expense




(40)

Other (expense) income, net

(61)


             3245


263


148

Interest expense

(442)



(442)


(372)

Profit before income taxes

3,931


1,540


5,471


4,845

Income tax expense

916


             3516


1,267


2,015

Net earnings

3,015


1,189


4,204


2,830

Less: Net earnings attributable to the non-controlling interest

7



7


98

Net earnings attributable to Kewaunee Scientific Corporation

$         3,008


$         1,189


$         4,197


$         2,732









Net earnings per share attributable to Kewaunee Scientific Corporation stockholders








Basic

$           1.05


$           0.41


$           1.46


$           0.94

Diluted

$           1.01


$           0.40


$           1.41


$           0.93



Six Months Ended October 31,


As Reported
2024


Professional &
Other Fees


Adjusted
2024


2023

Net sales

$      96,157


$              —


$       96,157


$    100,275

Cost of products sold

69,717



69,717


74,893

Gross profit

26,440



26,440


25,382

Operating expenses

19,431


          1,9467


17,485


16,465

Operating profit

7,009


1,946


8,955


8,917

Pension expense




(81)

Other income, net

266


             3248


590


223

Interest expense

(914)



(914)


(802)

Profit before income taxes

6,361


2,270


8,631


8,257

Income tax expense

1,108


             5189


1,626


2,912

Net earnings

5,253


1,752


7,005


5,345

Less: Net earnings attributable to the non-controlling interest

52



52


139

Net earnings attributable to Kewaunee Scientific Corporation

$         5,201


$         1,752


$         6,953


$         5,206









Net earnings per share attributable to Kewaunee Scientific Corporation stockholders








Basic

$           1.82


$            0.61


$            2.43


$           1.81

Diluted

$           1.75


$            0.59


$            2.34


$           1.79

______________________________

4 Professional fees incurred during the three months ended October 31, 2024 related to the Company's acquisition of Nu Aire

5 Cost incurred related to the early termination of the Company's Revolving Credit Facility

6 Estimated tax impact of professional and other fees incurred during the three months ended October 31, 2024 related to the Company's acquisition of Nu Aire

7 Professional fees incurred during the six months ended October 31, 2024 related to the Company's acquisition of Nu Aire

8 Cost incurred related to the early termination of the Company's Revolving Credit Facility

9 Estimated tax impact of professional and other fees incurred during the six months ended October 31, 2024 related to the Company's acquisition of Nu Aire

About Non-GAAP Measures 

The Company includes non-GAAP financial measures such as adjusted net earnings and adjusted net earnings per share, in the information provided with this press release as supplemental information relating to its operating results. Adjusted net earnings represents GAAP net earnings adjusted for professional and other fees related to the acquisition of Nu Aire, Inc. and the corresponding tax impact. This financial information is not in accordance with, or an alternative for, GAAP-compliant financial information and may be different from the operating or non-GAAP financial information used by other companies. The Company believes that this presentation of adjusted net earnings and adjusted net earnings per share provides useful information to investors regarding certain additional financial and business trends relating to its financial condition and results of operations.

EBITDA and Segment EBITDA are calculated as net earnings (loss), less interest expense and interest income, income taxes, depreciation, and amortization. Adjusted EBITDA and Adjusted Segment EBITDA are calculated as EBITDA or Segment EBITDA less the impact of the professional and other fees related to the Company's acquisition of Nu Aire, Inc., as discussed in more detail above. We believe EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA allow management and investors to compare our performance to other companies on a consistent basis without regard to depreciation and amortization or the professional fees not related to our core business incurred during the current period, which can vary significantly between companies depending upon many factors. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA are not calculations based upon generally accepted accounting principles, and the method for calculating EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA can vary among companies. The amounts included in the EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA calculations, however, are derived from amounts included in the historical consolidated statements of operations. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA should not be considered as alternatives to net earnings (loss) or operating earnings (loss) as an indicator of the Company's operating performance, or as an alternative to operating cash flows as a measure of liquidity.

About Nu Aire

Founded in 1971 and based in Minneapolis, the Company is a leading manufacturer of equipment for a diverse range of laboratory and pharmacy environments. Nu Aire is the North American market share leader in biological safety cabinets and other airflow products and also offers a complete line of CO2 incubators, ultralow freezers, animal handling equipment, pharmacy compounding isolators, and parts and accessories. Nu Aire's equipment is required for safety and quality in every type of laboratory: life sciences research, clinical, hospital, biotech and pharmaceutical R&D, academia, food and beverage, industrial and more. Nu Aire's website is located at http://www.nuaire.com/

About Kewaunee Scientific

Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.

The Company's corporate headquarters are located in Statesville, North Carolina. Sales offices are located in the United States, India, Saudi Arabia, and Singapore. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets. Kewaunee Scientific's website is located at http://www.kewaunee.com.  

This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to: our ability to realize the benefits anticipated as a result of the Nu Aire acquisition; competitive and general economic conditions, including disruptions from government mandates, both domestically and internationally, as well as supplier constraints and other supply disruptions; changes in customer demands; technological changes in our operations or in our industry; dependence on customers' required delivery schedules; risks related to fluctuations in the Company's operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; acts of terrorism, war, governmental action, and natural disasters and other Force Majeure events. The cautionary statements made pursuant to the Reform Act herein and elsewhere by us should not be construed as exhaustive. We cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. Over time, our actual results, performance, or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by our forward-looking statements, and such difference might be significant and harmful to our stockholders' interest. Many important factors that could cause such a difference are described under the caption "Risk Factors," in Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2024, which you should review carefully, and in our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. These reports are available on our investor relations website at www.kewaunee.com and on the SEC website at www.sec.gov. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Kewaunee Scientific Corporation

Condensed Consolidated Statements of Operations

(Unaudited)

($ and shares in thousands, except per share amounts)

 


Three Months Ended

October 31,


Six Months Ended

October 31,


2024


2023


2024


2023

Net sales

$       47,764


$       50,436


$       96,157


$     100,275

Cost of products sold

33,812


36,968


69,717


74,893

Gross profit

13,952


13,468


26,440


25,382

Operating expenses

9,518


8,359


19,431


16,465

Operating profit

4,434


5,109


7,009


8,917

Pension expense


(40)



(81)

Other (expense) income, net

(61)


148


266


223

Interest expense

(442)


(372)


(914)


(802)

Profit before income taxes

3,931


4,845


6,361


8,257

Income tax expense

916


2,015


1,108


2,912

Net earnings

3,015


2,830


5,253


5,345

Less: Net earnings attributable to the non-controlling interest

7


98


52


139

Net earnings attributable to Kewaunee Scientific Corporation

$          3,008


$          2,732


$          5,201


$          5,206









Net earnings per share attributable to Kewaunee Scientific Corporation stockholders








Basic

$            1.05


$            0.94


$            1.82


$            1.81

Diluted

$            1.01


$            0.93


$            1.75


$            1.79

Weighted average number of common shares outstanding








Basic

2,872


2,903


2,861


2,882

Diluted

2,974


2,931


2,971


2,908

 

Kewaunee Scientific Corporation

Condensed Consolidated Balance Sheets

($ in thousands)

 


October 31,
2024


April 30, 2024


(Unaudited)



Assets




Cash and cash equivalents

$           25,963


$           23,267

Restricted cash

3,701


2,671

Receivables, less allowances

41,885


45,064

Inventories

18,659


20,679

Prepaid expenses and other current assets

6,228


5,136

Total Current Assets

96,436


96,817

Net Property, Plant and Equipment

16,990


17,649

Right of use assets

6,941


7,454

Deferred income taxes

8,305


7,401

Other assets

5,806


5,445

Total Assets

$         134,478


$         134,766





Liabilities and Stockholders' Equity




Short-term borrowings

$                805


$             3,099

Current portion of lease obligations

2,221


2,234

Current portion of financing liability

750


713

Accounts payable

21,458


23,262

Other current liabilities

11,237


11,472

Total Current Liabilities

36,471


40,780

Long-term portion of lease obligations

5,191


5,669

Long-term portion of financing liability

27,032


27,420

Other non-current liabilities

5,127


4,688

Total Liabilities

73,821


78,557

Kewaunee Scientific Corporation Equity

59,328


54,760

Non-controlling interest

1,329


1,449

Total Stockholders' Equity

60,657


56,209

Total Liabilities and Stockholders' Equity

$         134,478


$         134,766

 

Contact:         

Donald T. Gardner III


704/871-3274

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kewaunee-scientific-reports-results-for-second-quarter-of-fiscal-year-2025-302329479.html

SOURCE Kewaunee Scientific Corporation

Ausgewählte Hebelprodukte auf Kewaunee Scientific

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Kewaunee Scientific

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Kewaunee Scientific CorpShs

Analysen zu Kewaunee Scientific CorpShs

DatumRatingAnalyst
27.08.2007Kewaunee mit Startposition Fuß in die TürHot Stocks Investor
DatumRatingAnalyst
27.08.2007Kewaunee mit Startposition Fuß in die TürHot Stocks Investor
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Kewaunee Scientific CorpShs nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"